Overview

Pulmozyme for Sjogren's Associated Cough

Status:
Withdrawn
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
Patients with Sjogren's disease have destruction of the mucus secreting cells in the airway. This manifestation of the disease leads to the common complaint of persistent dry cough that is seen in many of these patients. This study is aimed at determining whether the regular use of Pulmozyme will result in decreased cough and improved quality of life.
Phase:
Phase 1
Details
Lead Sponsor:
UConn Health